论文部分内容阅读
目的观察平阳霉素治疗小儿皮肤海绵状血管瘤的疗效。方法选择2006年5月—2013年4月收治的小儿皮肤海绵状血管瘤患者277例,采用平阳霉素注射治疗,根据患儿血管瘤体积注射平阳霉素,剂量为1 mg/cm3,每次注射量不超过8 mg。按照治愈、显效、好转、无效评价疗效。结果治愈率92.1%,显效率4.3%,好转率3.6%,有效率96.4%,无一例患儿发生过敏性休克。结论采用平阳霉素注射治疗小儿皮肤海绵状血管瘤安全、有效,与放射性核素32P胶体注射治疗有效率相近,且避免了32P胶体注射治疗的缺点。平阳霉素中未加利多卡因,可防止利多卡因导致的过敏性休克。
Objective To observe the curative effect of pingyangmycin in treating children’s skin cavernous hemangioma. Methods A total of 277 children with skin cavernous hemangioma from May 2006 to April 2013 were treated with Pingyangmycin injection. According to the volume of hemangioma in children, bleomycin was injected at a dose of 1 mg / cm3, Injection does not exceed 8 mg. In accordance with the cure, markedly effective, improved, ineffective evaluation of efficacy. Results The cure rate was 92.1%, markedly effective rate 4.3%, improvement rate 3.6%, effective rate 96.4%, no case of anaphylactic shock in children. Conclusion Pingyangmycin injection for the treatment of children with cavernous hemangioma is safe and effective, with 32P colloid injection of radionuclide effective treatment efficiency, and to avoid the shortcomings of 32P colloid injection therapy. Pingyangmycin without lidocaine, to prevent lidocaine-induced anaphylactic shock.